Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.59 EUR | +0.63% |
|
-2.45% | -3.64% |
Jun. 06 | I-Mab Appoints Phillip Dennis as Chief Medical Officer | CI |
Jun. 05 | I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers | MT |
Chart calendar I-Mab
Upcoming events on I-Mab
Past events on I-Mab
2024-06-05 09:30 am | Jefferies Global Healthcare Conference |
2024-04-11 10:15 am | Needham Healthcare Conference |
2024-03-14 05:00 pm | Q4 2023 Earnings Release |
2023-11-30 08:30 am | Piper Sandler Healthcare Conference |
2023-11-14 05:30 am | Jefferies London Healthcare Conference |
2023-11-04 12:00 pm | Society for Immunotherapy of Cancer Meeting - Poster #: 792 |
2023-11-03 12:00 pm | Society for Immunotherapy of Cancer Meeting - Abstract ID: 845 |
2023-10-23 06:00 am | European Society for Medical Oncology Congress |
2023-09-26 02:10 pm | Cantor Global Healthcare Conference |
2023-09-11 11:30 am | H.C. Wainwright Global Investment Conference |
2023-08-17 08:00 am | Q2 2023 Earnings Call |
2023-08-17 06:00 am | Q2 2023 Earnings Release |
2023-06-03 08:00 am | American Society of Clinical Oncology Conference - Abstract No: 2570 |
2023-03-31 08:15 am | Q4 2022 Earnings Call |
2023-03-31 06:30 am | Q4 2022 Earnings Release |
2022-12-12 06:00 pm | American Society of Hematology Meeting - Abstract ID: 4462 |
2022-12-12 06:00 pm | American Society of Hematology Meeting - Abstract ID: 3974 |
2022-11-10 09:00 am | Society for Immunotherapy of Cancer Meeting - Abstract ID : 859 |
2022-11-10 09:00 am | Society for Immunotherapy of Cancer Meeting - Abstract ID: 1151 |
2022-09-12 | European Society for Medical Oncology Congress - Abstract #3823 |
Annual results
Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 4,23 9,87 -57.18% | 236 185 27.81% | 13,8 84,4 -83.64% | -32,1 38,2 -183.99% | 3,89 2,72 43.36% | 0,75 |
EBITDA Million USD | Released Forecast Spread | -206 -171 -20.02% | 26,2 67,6 -61.22% | -311 -174 -78.68% | -268 -213 -26.01% | 0,00 0,00 - | 0,00 |
EBIT Million USD | Released Forecast Spread | -206 -118 -74.27% | 23,8 34,5 -31.11% | -325 -179 -81.39% | -272 -232 -17.28% | -174 -168 -3.59% | -152 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -205 -62,7 -226.47% | 73,9 37,2 98.35% | -366 -194 -88.63% | -350 -246 -41.96% | -206 -200 -3.02% | -143 |
Net income Million USD | Released Forecast Spread | -209 -62,7 -233.9% | 72,0 33,7 113.85% | -366 -195 -88.03% | -350 -246 -42% | -206 -200 -3.02% | -143 |
EPS USD | Released Forecast Spread | -65,4 -1,08 -5937.96% | 1,06 0,32 231.56% | -2,10 -1,83 -14.61% | -4,24 -2,08 -103.95% | -2,33 -1,77 -31.75% | -1,44 |
Announcement Date | 31/03/20 | 29/03/21 | 29/03/22 | 31/03/23 | 14/03/24 | - |
Quarterly results
Fiscal Period | December | 2020 S1 | 2020 S2 | 2021 S1 | 2021 Q4 | 2021 S2 | 2022 Q1 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2022 S2 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 S2 | 2024 Q1 | 2024 Q2 | 2024 S1 | 2024 Q3 | 2024 Q4 | 2024 S2 | 2025 Q1 | 2025 S1 | 2025 S2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 236 196 20.47% | 2,75 11,2 -75.42% | 5,32 0,00 - | 11,0 73,0 -84.89% | 3,60 0,00 - | 3,60 0,00 - | 7,74 20,0 -61.29% | 0,00 | 0,00 | -39,9 25,0 -259.46% | 0,00 | 0,00 | 2,71 3,00 -9.63% | 1,18 0,00 - | 0,00 | 0,00 | 0,75 | 0,00 | 0,00 | 0,75 | 0,00 | 0,00 | 0,00 |
EBIT Million USD | Released Forecast Spread | -86,9 -64,3 -35.09% | 118 112 5.15% | -159 -109 -45.31% | -73,8 -87,3 15.48% | -164 -55,4 -196.14% | -56,9 -88,8 35.9% | -56,9 -90,3 36.98% | -122 -153 19.97% | -87,6 | -133 | -149 -88,8 -67.95% | -53,9 | -53,1 | -92,6 -95,6 3.11% | -81,4 -84,7 3.84% | -43,8 | -45,2 | -85,3 | -47,3 | -48,2 | -84,7 | -48,6 | ||
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -82,5 -63,5 -29.92% | 163 102 59.13% | -167 -130 -28.68% | -95,0 -87,3 -8.8% | -197 -81,5 -141.56% | -72,6 -88,8 18.22% | -72,6 -90,3 19.58% | -156 -169 7.61% | -87,6 | -133 | -112 | -53,9 | -53,1 | -107 -113 5.57% | -99,9 -97,3 -2.69% | -43,8 | -45,2 | -78,5 | -47,3 | -48,2 | -65,6 | -48,6 | -54,2 | -54,2 |
Net income Million USD | Released Forecast Spread | -82,5 -63,5 -29.92% | 161 102 57.3% | -167 -130 -28.31% | -95,0 -87,3 -8.8% | -197 -81,5 -141.55% | -72,6 -88,8 18.22% | -72,6 -90,3 19.58% | -156 -169 7.61% | -87,6 | -133 | -112 | -53,9 | -53,1 | -107 -113 5.57% | -99,9 -97,3 -2.69% | -43,8 | -45,2 | -78,5 | -47,3 | -48,2 | -65,6 | -48,6 | -54,2 | -54,2 |
EPS USD | Released Forecast Spread | -1,56 -1,10 -41.6% | 2,62 1,21 116.29% | -2,28 -1,25 -82.74% | -1,21 -0,51 -136.9% | -1,09 -1,28 14.54% | -0,88 -0,48 -83.73% | -0,88 -0,48 -82.59% | -1,90 -1,79 -5.99% | -0,47 | -0,70 | -2,34 -1,08 -116.67% | -0,28 | -0,27 | -1,28 -1,31 2.29% | -1,05 -0,85 -24.04% | -0,22 | -0,22 | -0,55 | -0,23 | -0,24 | -0,48 | -0,23 | -0,25 | -0,25 |
Announcement Date | 31/08/20 | 29/03/21 | 31/08/21 | 29/03/22 | 29/03/22 | 10/11/22 | 30/08/22 | 30/08/22 | - | - | 31/03/23 | - | - | 17/08/23 | 14/03/24 | - | - | - | - | - | - | - | - | - |
Past sector events for I-Mab
2024-06-21 11:28 am | DEVA HOLDING: Q1 2024 Earnings Release |
2024-06-13 05:21 pm | EIS ECZACIBASI ILAÇ, SINAI VE FINANSAL YATIRIMLAR SANAYI VE TICARET: Q1 2024 Earnings Release |
2024-06-11 01:30 am | BORA PHARMACEUTICALS CO., LTD.: June 2024 Sales and Revenue Release |
2024-06-07 06:33 am | SCINOPHARM TAIWAN, LTD.: May 2024 Sales and Revenue Release |
2024-06-07 05:17 am | LOTUS PHARMACEUTICAL CO., LTD.: May 2024 Sales and Revenue Release |
2024-05-30 08:08 am | SUVEN PHARMACEUTICALS LIMITED: Q4 2024 Earnings Release |
2024-05-30 07:00 am | ROIVANT SCIENCES LTD.: Q4 2023 Earnings Release |
2024-05-30 02:24 am | MARKSANS PHARMA LIMITED: Q4 2024 Earnings Release |
2024-05-29 08:00 am | FDC LIMITED: Q4 2024 Earnings Release |
2024-05-29 05:26 am | JUBILANT PHARMOVA LIMITED: Q4 2024 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- IMAB Stock
- 0VY Stock
- Calendar I-Mab